Completed PHASE4 INTERVENTIONAL NCT00942214

Biomarkers and Response to Natalizumab for Multiple Sclerosis Treatment (Bionat2)

Biomarkers Associated With Response to Natalizumab in Multiple Sclerosis Patients. A Prospective Multicentric Open Label Phase IV Study

Sponsor: University Hospital, Toulouse

Conditions Multiple Sclerosis

Interventions Natalizumab

Updated 5 times since 2017 Last updated: Mar 29, 2011 Started: Jun 30, 2009 Primary completion: Feb 28, 2011 Completion: Mar 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Multiple Sclerosis, this trial is completed. The trial is conducted by University Hospital, Toulouse and has accumulated 5 data snapshots since 2009. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Jun 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University Hospital, Toulouse

Data source: University Hospital, Toulouse

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Toulouse, France